← Back to Search

RNA Therapy

ARCT-810 for Urea cycle disorder

Phase 1
Waitlist Available
Research Sponsored by Arcturus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks

Summary

This trial tests ARCT-810, a new treatment for patients with a specific condition, to see if it is effective and well-tolerated. The treatment aims to help the body better process waste products.

Eligible Conditions
  • Urea cycle disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence, severity and dose-relationship of adverse events (AEs)
Secondary study objectives
AUC0-inf after single dose of ARCT-810
AUCExtrap after single dose of ARCT-810
CL after single dose of ARCT-810
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ARCT-810Experimental Treatment1 Intervention
Ascending single doses of ARCT-810 administered intravenously
Group II: PlaceboPlacebo Group1 Intervention
Single doses of 0.9% Saline administered intravenously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARCT-810
2020
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Arcturus Therapeutics, Inc.Lead Sponsor
12 Previous Clinical Trials
22,435 Total Patients Enrolled
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top